Advertisement
AMGN vs BMY
Which Stock Would AI Choose? Amgen (AMGN) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- Amgen (AMGN) delivered double-digit revenue and earnings growth in 2025, powered by a diversified portfolio and an expanding pipeline led by the obesity candidate MariTide.
- Bristol-Myers Squibb (BMY) is navigating a major transition: its Growth Portfolio surged 17% in 2025, but legacy drug erosion continues to weigh on overall revenue.
- Amgen's forward price-to-earnings (P/E) ratio sits notably higher than BMY's, reflecting the market's confidence in its near-term growth trajectory.
- BMY offers a substantially higher dividend yield — roughly 5.3% versus Amgen's approximately 3% — appealing to income-oriented investors.
- Both companies face patent cliffs and biosimilar competition, but Amgen's broader diversification and revenue momentum currently give it an edge in relative performance.
- Amgen shares outperformed the S&P 500 in 2025, while BMY lagged, highlighting a divergence in market sentiment.
Introduction
AMGN and BMY represent two of the largest and most established biotechnology companies in the world. Both command extensive drug portfolios spanning oncology, cardiovascular disease, immunology, and rare diseases. Yet their recent trajectories tell markedly different stories. Amgen has been riding a wave of volume-driven revenue growth and pipeline enthusiasm, while Bristol-Myers Squibb is working through a challenging legacy-portfolio transition even as its newer medicines gain traction. This comparison is particularly relevant for investors weighing growth against value, and for those seeking to understand how two industry leaders are positioning themselves amid patent expirations, pricing pressures, and the next generation of drug innovation.
AMGN Overview and Recent Performance
Amgen, headquartered in Thousand Oaks, California, is a global biotechnology pioneer with a portfolio that addresses conditions ranging from high cholesterol and osteoporosis to severe asthma, rare diseases, and multiple cancer types. The company generated $36.8 billion in total revenue for full-year 2025, reflecting a 10% year-over-year increase driven by 13% volume growth. Eighteen products achieved record sales during the year, and fourteen surpassed $1 billion in annual revenue.
Several key medicines have been standout performers in recent quarters. Repatha, Amgen's cholesterol-lowering therapy, grew approximately 40% year over year, while TEZSPIRE, a treatment for severe asthma, posted similarly strong double-digit gains. The rare disease portfolio — bolstered by the Horizon Therapeutics acquisition — contributed meaningfully, with UPLIZNA and TAVNEOS both generating robust growth. Amgen's biosimilar business has also matured into a roughly $3 billion annualized revenue stream, with recent launches of WEZLANA (a biosimilar to Stelara) and PAVBLU (a biosimilar to Eylea) adding momentum.
Investor attention has centered on MariTide, Amgen's investigational obesity treatment that completed enrollment in two pivotal Phase 3 trials within roughly six months — a pace that underscores strong clinical and commercial interest. Meanwhile, the company faces headwinds from patent expirations on Prolia and XGEVA, with biosimilar competitors entering the U.S. market. Amgen's share price rose approximately 26% in 2025, outpacing the S&P 500, and the company has raised its dividend for fourteen consecutive years.
BMY Overview and Recent Performance
Bristol-Myers Squibb, based in Princeton, New Jersey, is a biopharmaceutical leader with deep expertise in oncology, hematology, cardiovascular disease, and immunology. In 2025, the company reported $48.2 billion in total revenue — essentially flat compared to the prior year — as robust growth in its newer medicines was offset by steep declines in its Legacy Portfolio. Non-GAAP (non-Generally Accepted Accounting Principles) earnings per share came in at $6.15 for the year.
The Growth Portfolio, which includes drugs such as BMY's immuno-oncology therapies, Breyanzi, Reblozyl, Camzyos, and the recently launched schizophrenia treatment Cobenfy, surged 17% to $26.4 billion. Breyanzi, a CAR T-cell therapy, more than doubled its sales year over year, while Reblozyl surpassed $2 billion in annual revenue. Opdivo, the company's flagship cancer immunotherapy, continues to perform steadily, aided by the launch of a subcutaneous formulation (Opdivo Qvantig) that enhances patient convenience.
The Legacy Portfolio, however, contracted approximately 15% as generic competition eroded sales of Revlimid, Pomalyst, Sprycel, and Abraxane. Eliquis, the blood thinner co-commercialized with Pfizer, remains the company's single largest revenue contributor but faces its own patent cliff in Europe. BMY has pursued an aggressive cost-savings initiative, targeting $2 billion in productivity improvements, and has reinforced its pipeline through acquisitions including the $1.5 billion purchase of Orbital Therapeutics. The company raised its dividend for the 17th consecutive year, with shares offering a yield near 5.3%. Despite this, BMY shares have underperformed the broader market in recent months as investors weigh the pace of the Growth Portfolio's expansion against the drag from legacy erosion.
Trending AI Robots
For investors seeking a data-driven edge in navigating comparisons like this one, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the most consistently effective and currently well-suited strategies earn a place in the Trending AI Robots section. These bots employ a wide variety of trading styles, timeframes, and risk profiles — from short-term momentum strategies to longer-term trend-following approaches — and each bot operates with its own unique statistical profile, including win rates, Sharpe ratios, and historical performance metrics. Whether you are evaluating individual stocks like AMGN or BMY or scanning the broader market for opportunity, exploring the Trending AI Robots page can provide timely, quantitatively grounded insight into where AI-driven strategies see the most potential right now.
Head-to-Head Comparison
Business Model and Scale. Amgen operates with a dual focus on innovative branded therapies and biosimilars, giving it a diversified revenue base that spans both proprietary and follow-on biologic medicines. Bristol-Myers Squibb is more concentrated in branded pharmaceuticals, with particular strength in oncology and hematology. BMY's top line is larger — $48.2 billion in 2025 versus Amgen's $36.8 billion — but Amgen's revenue is growing at a faster rate.
Growth Trajectory. Amgen's revenue grew 10% in 2025, supported by broad-based volume gains and new product launches. BMY, by contrast, posted flat revenue as its 17% Growth Portfolio expansion was neutralized by double-digit declines in legacy drugs. Looking ahead, Amgen's 2026 guidance implies continued growth, while BMY projects a modest revenue decline of 1% to 5% for 2026, reflecting the ongoing impact of generic competition.
Pipeline Catalysts. Both companies have meaningful late-stage programs. Amgen's MariTide in obesity — a market projected to reach $100 billion — is the most closely watched asset, with multiple Phase 3 readouts expected. BMY's pipeline is rich in oncology and immunology, with six potential new product readouts and several label expansion opportunities expected in the near term. Cobenfy's early launch trajectory in schizophrenia is a particularly important signal for BMY's neuroscience ambitions.
Risk Factors. Amgen must manage the ongoing erosion of Prolia and XGEVA, its two largest legacy drugs, as biosimilar competition intensifies. BMY faces a steeper patent cliff across Revlimid, Pomalyst, Sprycel, and eventually Eliquis. Both companies are exposed to U.S. drug pricing reforms under the Inflation Reduction Act (IRA), with select products already subject to Medicare price negotiations.
Valuation and Income. Amgen trades at a forward P/E ratio in the mid-teens, a premium to BMY's single-digit forward P/E. This gap reflects the market's expectation of stronger near-term earnings growth from Amgen. BMY's dividend yield, however, is substantially higher at over 5%, and the payout ratio remains below 50%, suggesting the dividend is well-covered. Amgen's yield, near 3%, is still well above the S&P 500 average.
Tickeron AI Verdict
Based on observable trend consistency, relative revenue momentum, and the balance of growth drivers versus legacy headwinds, Tickeron's AI-driven analysis would likely lean more favorably toward AMGN in the current environment. Amgen's combination of double-digit top-line growth, a diversified portfolio that spans both innovative medicines and biosimilars, and a high-profile obesity pipeline candidate provides a more durable foundation for positive price momentum. BMY's transformation is progressing, and its Growth Portfolio is genuinely impressive, but the persistent drag from its Legacy Portfolio introduces greater uncertainty into the near-term earnings trajectory. The AI's probabilistic assessment would likely recognize Amgen's steadier upward trend and broader catalyst base as more aligned with conditions favoring continued relative outperformance. That said, BMY's depressed valuation and high dividend yield could attract a different class of algorithmically driven strategies — particularly those oriented toward value and income — making both stocks worthy of ongoing monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and BMY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 3 bearish.
- BMY’s TA Score: 6 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.66% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BMY | AMGN / BMY | |
| Capitalization | 203B | 127B | 160% |
| EBITDA | 16.7B | 15B | 111% |
| Gain YTD | 16.558 | 18.999 | 87% |
| P/E Ratio | 26.17 | 17.39 | 150% |
| Revenue | 37.2B | 48.5B | 77% |
| Total Cash | 12B | N/A | - |
| Total Debt | 57.3B | 46.4B | 123% |
AMGN | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 18 | 83 | |
SMR RATING 1..100 | 12 | 25 | |
PRICE GROWTH RATING 1..100 | 21 | 14 | |
P/E GROWTH RATING 1..100 | 57 | 54 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as AMGN (10) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (18) in the Biotechnology industry is somewhat better than the same rating for BMY (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than BMY’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as BMY (25) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as AMGN (21) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.
BMY's P/E Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as AMGN (57) in the Biotechnology industry. This means that BMY’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | BMY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 41% | N/A |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 61% | 3 days ago 59% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 59% | 3 days ago 57% |
| Advances ODDS (%) | 3 days ago 59% | 3 days ago 54% |
| Declines ODDS (%) | 7 days ago 51% | 26 days ago 55% |
| BollingerBands ODDS (%) | 3 days ago 48% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 67% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.22% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.78% | ||
| PFE - AMGN | 52% Loosely correlated | -0.16% | ||
| GILD - AMGN | 52% Loosely correlated | -1.18% | ||
| MRK - AMGN | 50% Loosely correlated | +0.45% | ||
| ABBV - AMGN | 47% Loosely correlated | +0.95% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.